



UNDERSTANDING COVID-19 VACCINES

Helping employers plan their vaccination strategies

Version: August 20, 2021

From the onset of the COVID-19 pandemic, Cigna has focused on delivering peace of mind to the people and businesses we serve. With three COVID-19 vaccines having received FDA Emergency Use Authorization (EUA), Cigna is partnering with employers, like you, to help plan for vaccine administration of employees and their dependents, taking into account vaccine availability; how your workforce fits into the phased rollout (e.g., essential workers); and what you can do to prepare. We are pleased to provide answers to your common questions.

Together, all the way.®



Content is for informational purposes only, based on current information and subject to change. Please follow official guidance provided by local health authorities and government officials when developing reopening plans to meet the unique needs and characteristics of each location and workforce population.

Recently Updated

- How necessary is the vaccine for those ages 12 and up? (page 5)
- How long will the vaccine last? Will a booster be needed? (page 6)
- If I am pregnant or breast feeding, is it recommended that I get a COVID-19 vaccine? (page 7)
- Can employers raise premium costs for individuals who choose to decline the COVID-19 vaccination as their personal choice, which could impact their own health as well as others participating in our health plan? (page 8)
- Will the current vaccines protect against known emerging variants of concern including Delta? (page 9)
- Can health plans exclude coverage for COVID-19 treatment and testing for unvaccinated employees? (page 9)
- Is there a tool available to report side effects for my child? (page 12)
- What do we do now that some employees are fully vaccinated? (page 13)

What COVID-19 vaccines are available?

In the United States, there are currently three vaccines to prevent COVID-19 that are FDA-approved for Emergency Use Authorization (EUA). The manufacturers are Pfizer-BioNTech, Moderna, and Johnson & Johnson (J&J) /Janssen Biotech.

Who is eligible to receive a COVID-19 vaccine and where are they administered?

Everyone 12 years of age and older is now eligible to get a COVID-19 vaccination. There are several ways you can look for vaccination providers near you.

- **Visit [Vaccines.gov](https://www.vaccines.gov)** to find vaccination providers near you. In some states, information may be limited while more vaccination providers and pharmacies are being added. Learn more at [COVID-19 Vaccination FAQs on Vaccines.gov](#).
- Text your **zip code** to **438829** or call **1-800-232-0233** to find vaccine locations near you.
- **Check your local pharmacy's website to see if vaccination appointments are available.** Find out which pharmacies are participating in the [Federal Retail Pharmacy Program](#).
- **Contact your [state health department](#)** to find additional vaccination locations in the area.
- **Check your local news outlets.** They may have information on how to get a vaccination appointment.

Will the COVID vaccine be covered under preventive services (similar to flu vaccine) under Cigna plans now and in the future?

Yes. Any EUA-approved vaccine is covered as a preventive service. As such, a covered individual's out-of-pocket cost for the COVID-19 vaccine will be \$0. If other services are provided at the time of vaccine administration, such as a chronic condition evaluation, then cost-share for these services may be applied.

Keep in mind, the federal government is distributing doses of COVID-19 vaccine serum free of cost, and has mandated that non-exempt health plans and ASO employers pay 100% of the cost of administration of the vaccine, whether administered by health care professionals or pharmacists and whether in- or out-of-network. For all EUA-approved COVID-19 vaccines that are now (and become) available, Cigna's payment for vaccine administration is at the [established national CMS rates](#) when billed under the medical benefit.

Can you explain the difference between the vaccines and whether someone should choose one over the other? How will we know that a vaccine is both safe and effective?

The best vaccine choice is the vaccine available at the first available appointment. All three EUA-approved vaccines do an excellent job of preventing moderate to severe disease, hospitalizations and death. Long-term data is needed to learn how long the vaccines remain effective and what the impact of variants might be. People who feel uncomfortable symptoms within three weeks after getting a vaccination should contact their health care provider. Please refer to the [CDC website](#) for more details.

DIFFERENT COVID-19 VACCINES

	Pfizer-BioNTech	Moderna	J&J/ Janssen
STORAGE DETAILS¹	Dry ice freezing ¹	Refrigerator 30 days	Simple refrigeration
DOSING SCHEDULE¹	2 injections, 3 weeks apart	2 injections, 4 weeks apart	1 injection
AGE GROUP³	12+	18+	18+
EFFICACY: PREVENTING MODERATE TO SEVERE DISEASE	95% ²	94.5% ²	72% ^{2,4}
EFFICACY: PREVENTING SEVERE COVID-19 DISEASE	100% ³	100% ³	85% ³
EFFICACY: PREVENTING COVID-19 DEATHS (Trial data)	No deaths ³	No deaths ³	No deaths ⁵
MECHANISM²	mRNA	mRNA	Adenovirus vector
STATUS²	FDA Emergency Authorization granted Dec. 11, 2020	FDA Emergency Authorization granted Dec. 18, 2020	FDA Emergency Authorization granted Feb. 27, 2021

1. Federal Drug Administration, (2021, May 19). FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available [Press release]. 2. Zimmer, Carl, et al. Coronavirus Vaccine Tracker. The New York Times. Last updated June 24, 2021. 3. Kaplan, Karen. How the Moderna and Pfizer COVID-19 vaccines compare head to head. Los Angeles Times. Dec. 15, 2020. 4. Efficacy rates in U.S. trials and Centers for Disease Control and Prevention (2021, June, 21) COVID-19 Breakthrough Case Investigations and Reporting. 5. Jnj.com. Jan. 29, 2021.

How necessary is the vaccine for those ages 12 and up?

It is incredibly important that everyone 12 years of age and older receive a vaccine when available. The CDC approved the Pfizer-BioNTech COVID-19 vaccine for children ages 12 and up and recommends that adolescents start getting vaccinated right away. The American Academy of Pediatrics and CDC now recommend that all children over age 2 wear masks when they return to school this year, regardless of vaccination status.

Though most children with COVID-19 have mild or no symptoms, some can get severely ill and require hospitalization. Some variants appear to be more contagious and affect children more than earlier ones. The Delta variant now accounts for more than 83 percent of COVID-19 cases, the Centers for Disease Control and Prevention said on July 21. Currently available vaccines still protect against known variants of concern. There are still unknowns regarding long-term effects of COVID-19 caused by inflammation that is often not apparent during the initial illness.

We encourage parents with questions about the vaccine to talk with their child's health care provider. Experts believe vaccines could be available for children under 12 years old as early as September and as late as the first quarter of 2022, but clinical trials remain ongoing before data can be delivered to the FDA for EUA consideration. There are a number of excellent articles and guidance that can be found on the American Academy of Pediatrics Healthy Children site. Click the following link <https://www.healthychildren.org/English/health-issues/conditions/COVID-19/Pages/default.aspx>.

For more information, see the [CDC director statement about the Pfizer-BioNTech COVID-19 vaccine](#), the [FDA decision to authorize emergency use of this vaccine in 12- through 15-year-old adolescents](#) or view CDC presentation slides [here](#).

Are there ongoing trials for those younger than age 12? If so, is there a forecast for FDA approval?

The CDC approved the use of the Pfizer-BioNTech COVID-19 vaccine in 12- to 15-year-olds after the manufacturer completed safety and effectiveness studies on patients in this age group. Trial results for safety and effectiveness in populations under age 12 are expected. Other manufacturers are expected to complete studies and seek approval to expand administration of their vaccines to younger patients as well. Moderna recently requested EUA expansion for its COVID-19 vaccine for ages 12 and up, and it is currently under review.

How long will the vaccine last? Will a booster be needed?

The COVID-19 vaccines authorized in the United States continue to be remarkably effective in reducing risk of severe disease, hospitalization, and death, even against the widely circulating Delta variant. Recognizing that many vaccines are associated with a reduction in protection over time, and acknowledging that additional vaccine doses could be needed to provide long lasting protection, evidence has been analyzed carefully from the United States and around the world to understand how long protection will last and how to improve protection. The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the Delta variant, evidence of reduced protection against mild and moderate disease has been noted. Based on the latest assessment, the current protection against severe disease, hospitalization, and death could diminish in the months ahead, especially among those who are at higher risk or were vaccinated during the earlier phases of the vaccination rollout. For that reason, experts conclude that a booster shot will be needed to maximize vaccine-induced protection and prolong its durability.

Issued August 18, 2021: [Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots.](#)

A plan to begin offering these booster shots this fall has been recommended, subject to FDA conducting an independent evaluation and determination of the safety and effectiveness of a third dose of the Pfizer and Moderna mRNA vaccines and CDC's Advisory Committee on Immunization Practices (ACIP) issuing booster dose recommendations based on a thorough review of the evidence. HHS are prepared to offer booster shots for all Americans beginning the week of September 20 and starting 8 months after an individual's second dose. At that time, the individuals who were fully vaccinated earliest in the vaccination rollout, including many health care providers, nursing home residents, and other seniors, will likely be eligible for a booster. For more information, click this link:

<https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html>

As of August 13, 2021, the CDC is recommending that moderately to severely immunocompromised people receive an additional dose. This includes people who have:

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., ≥ 20 mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory.

For more information regarding immunocompromised patients, click [here](#).

What is Cigna doing to reduce disparities in COVID-19 vaccine administration?

Cigna has recognized and worked to address health disparities for years, including those around vaccination. Examples of our current activities include:

1. Increased emphasis on education about vaccine concerns in our patient communication materials
2. Involving community leaders (city, faith-based, business) in efforts to improve awareness and access
3. Promoting implicit bias training for physicians
4. Broadly driving Social Determinants of Health/Health Disparities initiatives within all of our value-based clinical provider partnerships

Did COVID-19 clinical trials include diverse populations and were the outcomes or side effects different by race or gender?

Yes. Manufacturers provided demographic data for participants in their late-stage clinical trials. Similar vaccine efficacy and safety results were observed across racial and ethnic populations. For more information, see [kff.org](https://www.kff.org).

If I am pregnant or breast feeding, is it recommended that I get a COVID-19 vaccine?

Any of the currently authorized COVID-19 vaccines can be offered to people who are pregnant or breastfeeding. On July 30, the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM), the two leading organizations representing specialists in obstetric care, recommended that all pregnant individuals be vaccinated against COVID-19. If you have questions about getting vaccinated, a conversation with your health care provider might help, but may not be necessary.

According to the CDC, pregnant people are at increased risk for severe illness from COVID-19. Additionally, pregnant people with COVID-19 might be at increased risk of adverse pregnancy outcomes, such as preterm birth, compared with pregnant women without COVID-19. More information is available [here](#).

The Delta variant of COVID-19 poses a heightened risk of infection to everyone, particularly unvaccinated people, because it is more contagious.

A new [study](#), which comes from the United Kingdom Obstetric Surveillance System, found that hospital admissions of pregnant women with COVID-19 are increasing amid the spread of the Delta variant in the United Kingdom and that their illness is more severe than it was in previous waves.

Can employers buy vaccine to expedite the delivery to their workforce?

Non-healthcare employers do not have access to the vaccines purchased by the federal government. A [CDC COVID-19 Vaccination Program Provider Agreement](#) needs to be filed and an application completed on each state's health department portal. Employers interested in onsite vaccine events should work with their client services representative.

What are employers allowed to ask employees about the vaccine? Is the decision to vaccinate a medical decision protected by HIPAA? If not, why?

As the vaccine rollout continues and restrictions are eased, we recognize some employers are evaluating workplace rules. This requires thorough discussion with your legal counsel and human resources partner. Different factors come into play:

- **Can employers ask their employees to say when they've been vaccinated?**
 - a. HIPAA protects the confidentiality, integrity, and availability of personal health information. Employers may consider offering incentive programs that allow self-disclosure or self-attestation where the release of the health information is part of the consent to participate in the program. Employers cannot request health information for non-care coordination uses such as surveillance, site location opening, or other occupational reasons.
- **Can employers require that their employees get the vaccine?**
 - a. The U.S. Equal Employment Opportunity Commission issued guidance suggesting that employers can mandate COVID-19 vaccines as long as employees don't have a disability and/or a sincerely-held religious belief that would prevent them from getting vaccinated.
 - b. It's important to remember that COVID-19 vaccines have FDA Emergency Use Authorization approval. Under FDA rules for Emergency Use Authorization, the recipient has the right to either get it or refuse it. Mandating vaccines with EUA is problematic. However, recent court decisions and EEOC guidance support employer-mandated vaccination requirements for vaccines approved under EUA. For some employers, waiting for COVID-19 vaccines to receive full [Biologics License Application \(BLA\) approval](#) may be a more appropriate time to consider mandates. Policy makers and employers will need to determine which, if any, populations to which a vaccine mandate should apply. Post BLA, vaccine mandates could be imposed in multiple sectors, each with their own legal and ethical considerations.

It's never too soon to promote the value of getting the vaccine to your workforce. So, talk with your client services representative about our [Healthy Ways to Work](#) SM program to discuss ways to promote the importance and safety of these vaccines to help encourage employees.

Employers are able to increase plan premiums for employees who are active smokers and require work environments that are smoke free for the health of the overall workforce. Can employers raise premium costs for individuals who choose to decline the COVID-19 vaccination as their personal choice, which could impact their own health as well as others participating in our health plan?

Tobacco use premium surcharges are specifically permitted under the Affordable Care Act and Department of Labor rules. COVID-19 vaccine status may not be treated the same way. Therefore, we recommend employers consult with legal counsel before adjusting employee health plan contributions based upon participants' vaccination status.

Can health plans exclude coverage for COVID-19 treatment and testing for unvaccinated employees?

Cigna plans cannot exclude coverage based on COVID-19 vaccination status. The HIPAA non-discrimination provisions (Section 9802 of the Internal Revenue Code, section 702 of ERISA, and section 2702 of the PHS Act) establish rules prohibiting group health plans from discriminating against individual participants or beneficiaries based on any health factor. These rules specifically prohibit discriminatory practices related to member eligibility, enrollment processes, premium payments, or benefit design that purposely exclude a person or class of persons.

Will Cigna be able to host an onsite office vaccination event? I tell everyone to sign up with their state and local governments for vaccination ASAP and not wait for a company event. Is this the right strategy?

In many locations, state and government vaccine distribution sites have been pared back or eliminated since supply is robust and demand for vaccination has lessened. Increasingly, onsite options are or will be available for employers. We are taking a multi-pronged approach by working with onsite vendors, national retail pharmacy chains, and market providers to assist clients in coordinating onsite COVID-19 vaccine events when local vaccine priorities and supply allows.

Please talk to your client services representative if you are interested so they can add you to the onsite event list. We are making every effort to obtain vaccine and offer it to eligible employees. Visit [Vaccines.gov](https://www.vaccines.gov) for vaccination sites near you.

Will the current vaccines protect against known emerging variants of concern including Delta?

Each vaccine was designed using the original strain of the virus. Recent statements by both Pfizer-BioNTech and Moderna suggest that their vaccines do protect against emerging strains. J&J/Janssen also conducted a subgroup analysis in the United States, South Africa, and Brazil showing efficacy rates as part of the EUA-approval process.

While currently available vaccines appear protective against variants of concern at this time, it is important to understand that where community vaccination rates are low, variants will likely emerge that will not be responsive to current vaccines, leading to the need for modified booster vaccines and potentially new community COVID-19 restrictions depending on community circumstances. Fully vaccinated people with Delta variant, the most common variant currently circulating, may have breakthrough infections and could spread the virus to others. However, vaccinated people with breakthrough infections appear to be infectious for a shorter period of time and do not develop serious infections leading to hospitalization and/or death. No vaccines are 100% effective.

What are the rates of adverse events for COVID-19 vaccines? Should employees with existing allergic reactions to foods or other vaccines receive the COVID-19 vaccine?

The CDC indicates that while some people don't have any side effects after getting a COVID-19 vaccine, many people will have mild [side effects after vaccination](#). More severe reactions are extremely **rare** and can be treated. Patients are asked to stay for 15 to 30 minutes after getting a vaccine in order to be observed and provided treatment in the rare case it is needed. We encourage customers to discuss concerns with their health care provider.

Common COVID-19 vaccine topics of concern

Concern	Fact*
Speed of development	The vaccines are proven safe and effective, and they were developed quickly because of the worldwide effort. Although developed in record time, they have gone through the same rigorous FDA process as every other vaccine, meeting all safety standards. No steps were skipped.
Impact of RNA	mRNA is simply a message that the body reads. It cannot change your DNA or modify your genes.
Ingredients	mRNA vaccines are free of preservatives and only contain the mRNA, a fatty coating layer to protect the mRNA, PEG (polyethylene glycol), and a combination of salts, sugar and water. Viral vector COVID-19 vaccines use a harmless version of a different virus, called a "vector," to deliver information to the body that helps protect you.
Long-term data	Hundreds of millions have been vaccinated. Clinical trials have shown us the vaccines are safe, and now we are seeking long-term data to learn how long the vaccines remain effective.

* University of Waterloo School of Pharmacy and UC Davis Health, *Real facts about common COVID-19 vaccine myths*.

Myocarditis and pericarditis following mRNA COVID-19 vaccination

Since April 2021, there have been reports to the Vaccine Adverse Event Reporting System (VAERS) of cases of inflammation of the heart—called myocarditis and pericarditis—happening after mRNA COVID-19 vaccination (i.e., Pfizer-BioNTech, Moderna) in the United States. These reports are rare, given the hundreds of millions of vaccine doses administered, and have been reported after mRNA COVID-19 vaccination, particularly in adolescents and young adults. View the [latest information](#).

CDC continues to recommend COVID-19 vaccination for everyone 12 years of age and older, given the risk of COVID-19 illness and related, possibly severe complications. For more information, click [here](#).

Nerve damage and blood clots following the J&J/Janssen COVID-19 vaccination

CDC and FDA are monitoring reports of [Guillain-Barré Syndrome](#) (GBS) in people who have received the J&J/Janssen COVID-19 Vaccine. GBS is a rare disorder where the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Most people fully recover from GBS, but some have permanent nerve damage. After 12.8 million J&J/Janssen COVID-19 Vaccine doses administered, there have been around 100 preliminary reports of GBS identified. For more information, click [here](#).

After a temporary pause of J&J/Janssen COVID-19 vaccinations in the U.S. in April of this year, the [Advisory Committee on Immunization Practices](#) (ACIP), the [U.S. Centers for Disease Control and Prevention](#) (CDC) and the [U.S. Food and Drug Administration](#) (FDA) recommended that vaccinations with the J&J/Janssen COVID-19 vaccine resume, concluding that the benefits of the Janssen COVID-19 vaccine outweigh its known and potential risks in individuals 18 years and older. However, women younger than 50 years old should be aware of the rare but increased risk of thrombosis with thrombocytopenia syndrome (TTS). TTS is a serious condition that involves blood clots with low platelets. There are other COVID-19 vaccine options available for which this risk has not been seen.

What should my employees who already received or want to get the J&J/Janssen COVID-19 vaccine know about TTS?

According to the [CDC website](#), there is a plausible causal relationship between the J&J/Janssen COVID-19 vaccine and a rare and serious adverse event—blood clots with low platelets (thrombosis with thrombocytopenia syndrome, or TTS). However, after reviewing all available safety data, the CDC and FDA recommended use of this vaccine resume in the United States given that the known and potential benefits outweigh the known and potential risks.

What patients should know

TTS is a rare, adverse event, occurring at a rate of about seven per 1 million vaccinated women between 18 and 49 years old. For women 50 years and older and men of all ages, this adverse event is even more rare.

- For three weeks after receiving the vaccine, those vaccinated should be aware of possible symptoms of a blood clot with low platelets.
- **Patients should seek medical care right away if one or more of these symptoms develop:**
 - Severe or persistent headaches or blurry vision
 - Shortness of breath
 - Chest pain
 - Leg swelling
 - Persistent abdominal pain
 - Easy bruising or tiny blood spots under the skin beyond the injection site
- Health care providers administering the vaccine, vaccine recipients, and caregivers should review the [J&J/Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine](#) and [Fact Sheet for Recipients and Caregivers](#), which have been revised to include information about the risk of this syndrome, which has occurred in a very small number of people who received the J&J/Janssen COVID-19 vaccine.

Is there a tool available to report side effects for my child?

If your child has symptoms or health problems that concern you at any time following COVID-19 vaccination, please contact your child's health care provider.

V-safe, a smartphone-based tool, does not provide medical advice, however, parents and guardians can quickly tell CDC about any side effects their child may have after getting a COVID-19 vaccine.

V-safe uses text messaging and web surveys to provide personalized health check-ins after a COVID-19 vaccination. Depending on answers to the web surveys, someone from CDC may call parents or guardians to check in and get more information. V-safe will also send a reminder to get a second COVID-19 vaccine dose if it is needed. To enroll yourself in v-safe, click [Register for v-safe | CDC](#). To enroll your child, click [Enroll your Dependent in v-safe | CDC](#).

For additional information, see <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html>

What important points can employers share to address vaccine hesitancy?

Be honest with your employees. Provide the facts. Create a positive environment around vaccination. Set the example. Some key points to mention:

- The available vaccines are proven to be safe and effective.
- Although developed in record time, the available COVID-19 vaccines have gone through the same rigorous FDA process as every other vaccine, meeting all safety standards. Some factors that accelerated approval were funding, prioritization in the FDA pipeline, and high volume of available clinical trial participants. ***In other words, pharmaceutical manufacturers, clinicians, public health and governmental agencies were able to cut through the red tape that generally slows the development and approval process for vaccines.*** For example, recruiting clinical trial participants can take a long period of time and this was done quickly with COVID-19 vaccines.
- Clinical trials were completed through the usual process. No steps were skipped.
- More severe reactions are extremely rare and can be treated. Out of an abundance of safety after receiving the vaccine, patients are asked to stay 15 to 30 minutes after getting a vaccine in order to be observed and provided treatment in the rare case it is needed. Those who experience uncomfortable symptoms within three weeks after vaccination should contact their health care provider.
- We encourage individuals to talk with their health care provider if they have concerns.

What do we do now that some employees are fully vaccinated?

Based on information from the CDC, authorized vaccines in the United States are highly effective at protecting vaccinated people against symptomatic and severe COVID-19. Fully vaccinated people are less likely to become infected, and if infected, to develop symptoms of COVID-19. They are at substantially reduced risk of severe illness and death from COVID-19 compared with unvaccinated people.

Given new evidence on the B.1.617.2 (Delta) variant currently circulating in the United States, the CDC updated recommendations for fully vaccinated people as follows:

- On July 27, 2021, CDC released [updated guidance](#) on the need for urgently increasing COVID-19 vaccination coverage and a recommendation for everyone in areas of [substantial or high transmission](#) to wear a mask in public indoor places, even if they are fully vaccinated.
- The CDC recommends that fully vaccinated people who have a known exposure to someone with suspected or confirmed COVID-19 be tested 3-5 days after exposure, and wear a mask in public indoor settings for 14 days or until they receive a negative test result. Patients are advised to speak with their healthcare professional about the need for testing for asymptomatic or mild symptoms.
- The CDC recommends universal indoor masking for all teachers, staff, students, and visitors to schools, regardless of vaccination status.

According to the CDC, fully vaccinated people should:

- Get tested if experiencing [COVID-19 symptoms](#).
- Get tested 3-5 days following a known exposure to someone with suspected or confirmed COVID-19 and wear a mask in public indoor settings for 14 days after exposure or until a negative test result.
- Isolate if they have tested positive for COVID-19 in the prior 10 days or are experiencing [COVID-19 symptoms](#).
- Follow any applicable federal, state, local, tribal, or territorial laws, rules, and regulations.

The CDC also recommends that people who are immunocompromised should be counseled about the potential for reduced immune responses to COVID-19 vaccines and follow current prevention measures (including wearing a mask, staying 6 feet apart from others they don't live with, and avoiding crowds and poorly ventilated indoor spaces) regardless of their vaccination status to protect themselves against COVID-19 until advised otherwise by their health care provider.

More information about mask guidance and physical distancing is available [here](#). For the most up-to-date information, be sure to visit the [CDC website](#) regularly.

Employers should refer to local mandates for workplace guidance. For guidance about returning to work, we can offer resources based on some of the specific needs of your organization. Please visit [Cigna Healthy Ways to Work](#).SM

We also offer additional [resources and information](#) about returning to the worksite to help you keep your employees safe while working during COVID-19.

Helpful resources for employers

Below are links to important guidance and helpful information from the CDC, FDA, and other sources for your reference.

- ▶ [CDC COVID-19 Vaccine FAQ](#)
- ▶ [CDC COVID-19 Vaccines](#)
- ▶ [CDC COVID-19 Vaccine Planning Guide](#)
- ▶ [CDC COVID-19 Vaccination Recommendations](#)
- ▶ [CDC COVID-19 Vaccination Information Regarding Children](#)
- ▶ [Occupational Safety and Health Administration \(OSHA\) Regarding COVID-19](#)
- ▶ [U.S. Equal Employment Opportunity Commission \(EEOC\) Regarding COVID-19](#)
- ▶ [Cigna Coronavirus \(COVID-19\) Resource Center](#)
- ▶ [CDC Fully Vaccinated Guidance](#)
- ▶ [CDC Fully Vaccinated](#)
- ▶ [CDC COVID-19 Data Tracker](#)
- ▶ [Workplace COVID-19 Vaccine Toolkit | CDC](#)

Please visit [Vaccines.gov](https://www.vaccines.gov) to find a vaccine location.

In addition to federal guidelines, state and local health departments have resources to provide further information on COVID-19 vaccines. The CDC provides a link to accredited State Departments of Health [here](#) or visit [Cigna.com/vaccinesbystate](https://www.cigna.com/vaccinesbystate).

The National Association of County and City Health Officials (NACCHO) also provides links to local health departments [here](#).

952537a 08//2021

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation.

